Silence Therapeutics plc (SLN)

Market Cap	1.04B
Revenue (ttm)	32.12M
Net Income (ttm)	-54.77M
Shares Out	46.50M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,156
Open	22.49
Previous Close	22.51
Day's Range	22.08 - 22.80
52-Week Range	4.60 - 27.72
Beta	1.40
Analysts	Strong Buy
Price Target	57.25 (+157.07%)
Earnings Date	May 14, 2024

About SLN

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Craig A. Tooman M.B.A.
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: SLN

Financial Performance

In 2023, SLN's revenue was 25.38 million, an increase of 44.99% compared to the previous year's 17.50 million. Losses were -43.27 million, 6.86% more than in 2022.

Financial numbers in GBP

Analyst Forecast

According to 4 analysts, the average rating for SLN stock is "Strong Buy." The 12-month stock price forecast is $57.25, which is an increase of 157.07% from the latest price.

Price Target

$57.25

(157.07% upside)

Analyst Consensus: Strong Buy